Are growth factors the answer?

Parkinsonism and Related Disorders

Volumn 15, Issue SUPPL. 3, 2009, Pages

  Ramaswamy, Shilpa ^a   Kordower, Jeffrey H ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

GDNF; Gene therapy; Neurturin; Parkinson's disease; Trophic factors

Indexed keywords

ADENOVIRUS VECTOR; BRAIN DERIVED NEUROTROPHIC FACTOR; CERE 120; DOPAMINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GROWTH FACTOR; LENTIVIRUS VECTOR; LEVODOPA; MESENCEPHALIC ASTROCYTE DERIVED NEUROTROPHIC FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; NEUROTROPHIC FACTOR; NEURTURIN; OMEGA 3 FATTY ACID; PARVOVIRUS VECTOR; PLACEBO; SELEGILINE; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

ANOREXIA; ARTICLE; CLINICAL TRIAL; CORPUS STRIATUM; DEPRESSION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; EXPERIMENTAL MODEL; HUMAN; LOW DRUG DOSE; MOTOR DYSFUNCTION; NAUSEA; NERVE CELL DEGENERATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; SIDE EFFECT; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VOMITING; WEIGHT REDUCTION;

ANIMALS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; PARKINSON DISEASE;

EID: 71849091577     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(09)70809-0     Document Type: Article

References (51)

1. Levi-Montalcini R., Meyer H., and Hamburger V. In vitro experiments on the effects of mouse sarcomas 180 and 37 on the spinal and sympathetic ganglia of the chick embryo. Cancer Res 14 1 (1954) 49-57
2. Airaksinen M.S., and Saarma M. The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci 3 5 (2002) 383-394
3. Lindsay R.M. Neurotrophins and receptors. Prog Brain Res 103 (1994) 3-14
4. Hefti F. Neurotrophic factor therapy for nervous system degenerative diseases. J Neurobiol 25 11 (1994) 1418-1435
5. Barde Y.A., Edgar D., and Thoenen H. Purification of a new neurotrophic factor from mammalian brain. EMBO J 1 5 (1982) 549-553
6. Reichardt L.F. Neurotrophin-regulated signalling pathways. Philos Trans R Soc Lond B Biol Sci 361 1473 (2006) 1545-1564
7. Yan Q., Rosenfeld R.D., Matheson C.R., Hawkins N., Lopez O.T., Bennett L., et al. Expression of brain-derived neurotrophic factor protein in the adult rat central nervous system. Neuroscience 78 2 (1997) 431-448
8. Yan Q., Radeke M.J., Matheson C.R., Talvenheimo J., Welcher A.A., and Feinstein S.C. Immunocytochemical localization of TrkB in the central nervous system of the adult rat. J Comp Neurol 378 1 (1997) 135-157
9. Parain K., Murer M.G., Yan Q., Faucheux B., Agid Y., Hirsch E., et al. Reduced expression of brain-derived neurotrophic factor protein in Parkinson's disease substantia nigra. Neuroreport 10 3 (1999) 557-561
10. Zhang X., Andren P.E., and Svenningsson P. Repeated l-DOPA treatment increases c-fos and BDNF mRNAs in the subthalamic nucleus in the 6-OHDA rat model of Parkinson's disease. Brain Res 1095 1 (2006) 207-210
11. Gyarfas T., Knuuttila J., Lindholm P., Rantamaki T., and Castren E. Regulation of brain-derived neurotrophic factor (BDNF) and cerebral dopamine neurotrophic factor (CDNF) by anti-parkinsonian drug therapy in vivo. Cell Mol Neurobiol (2009)
12. Bousquet M., Gibrat C., Saint-Pierre M., Julien C., Calon F., and Cicchetti F. Modulation of brain-derived neurotrophic factor as a potential neuroprotective mechanism of action of omega-3 fatty acids in a parkinsonian animal model. Prog Neuropsychopharmacol Biol Psychiatry (2009)
13. Levivier M., Przedborski S., Bencsics C., and Kang U.J. Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease. J Neurosci 15 12 (1995) 7810-7820
14. Frim D.M., Uhler T.A., Galpern W.R., Beal M.F., Breakefield X.O., and Isacson O. Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. Proc Natl Acad Sci USA 91 11 (1994) 5104-5108
15. Klein R.L., Lewis M.H., Muzyczka N., and Meyer E.M. Prevention of 6-hydroxydopamine-induced rotational behavior by BDNF somatic gene transfer. Brain Res 847 2 (1999) 314-320
16. Tsukahara T., Takeda M., Shimohama S., Ohara O., and Hashimoto N. Effects of brain-derived neurotrophic factor on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in monkeys. Neurosurgery 37 4 (1995) 733-739
17. Petrova P., Raibekas A., Pevsner J., Vigo N., Anafi M., Moore M.K., et al. MANF: a new mesencephalic, astrocyte-derived neurotrophic factor with selectivity for dopaminergic neurons. J Mol Neurosci 20 2 (2003) 173-188
18. Zhou C., Xiao C., Commissiong J.W., Krnjevic K., and Ye J.H. Mesencephalic astrocyte-derived neurotrophic factor enhances nigral gamma-aminobutyric acid release. Neuroreport 17 3 (2006) 293-297
19. Voutilainen M.H., Back S., Porsti E., Toppinen L., Lindgren L., Lindholm P., et al. Mesencephalic astrocyte-derived neurotrophic factor is neurorestorative in rat model of Parkinson's disease. J Neurosci 29 30 (2009) 9651-9659
20. Lin L.F., Doherty D.H., Lile J.D., Bektesh S., and Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260 5111 (1993) 1130-1132
21. Pascual A., Hidalgo-Figueroa M., Piruat J.I., Pintado C.O., Gomez-Diaz R., and Lopez-Barneo J. Absolute requirement of GDNF for adult catecholaminergic neuron survival. Nat Neurosci 11 7 (2008) 755-761
22. Horger B.A., Nishimura M.C., Armanini M.P., Wang L.C., Poulsen K.T., Rosenblad C., et al. Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons. J Neurosci 18 13 (1998) 4929-4937
23. Treanor J.J., Goodman L., de Sauvage F., Stone D.M., Poulsen K.T., Beck C.D., et al. Characterization of a multicomponent receptor for GDNF. Nature 382 6586 (1996) 80-83
24. Trupp M., Arenas E., Fainzilber M., Nilsson A.S., Sieber B.A., Grigoriou M., et al. Functional receptor for GDNF encoded by the c-ret proto-oncogene. Nature 381 6585 (1996) 785-789
25. Marco S., Saura J., Perez-Navarro E., Jose M.M., Tolosa E., and Alberch J. Regulation of c-Ret, GFRalpha1, and GFRalpha2 in the substantia nigra pars compacta in a rat model of Parkinson's disease. J Neurobiol 52 4 (2002) 343-351
26. Worby C.A., Vega Q.C., Zhao Y., Chao H.H., Seasholtz A.F., and Dixon J.E. Glial cell line-derived neurotrophic factor signals through the RET receptor and activates mitogen-activated protein kinase. J Biol Chem 271 39 (1996) 23619-23622
27. van Weering D.H., and Bos J.L. Signal transduction by the receptor tyrosine kinase Ret. Recent Results Cancer Res 154 (1998) 271-281
28. Borrello M.G., Alberti L., Arighi E., Bongarzone I., Battistini C., Bardelli A., et al. The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma. Mol Cell Biol 16 5 (1996) 2151-2163
29. Kearns C.M., and Gash D.M. GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo. Brain Res 672 1-2 (1995) 104-111
30. Sauer H., Rosenblad C., and Bjorklund A. Glial cell line-derived neurotrophic factor but not transforming growth factor beta 3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion. Proc Natl Acad Sci USA 92 19 (1995) 8935-8939
31. Kirik D., Rosenblad C., and Bjorklund A. Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor. Eur J Neurosci 12 11 (2000) 3871-3882
32. Ai Y., Markesbery W., Zhang Z., Grondin R., Elseberry D., Gerhardt G.A., et al. Intraputamenal infusion of GDNF in aged rhesus monkeys: distribution and dopaminergic effects. J Comp Neurol 461 2 (2003) 250-261
33. Maswood N., Grondin R., Zhang Z., Stanford J.A., Surgener S.P., Gash D.M., et al. Effects of chronic intraputamenal infusion of glial cell line-derived neurotrophic factor (GDNF) in aged Rhesus monkeys. Neurobiol Aging 23 5 (2002) 881-889
34. Grondin R., Zhang Z., Yi A., Cass W.A., Maswood N., Andersen A.H., et al. Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. Brain 125 Pt 10 (2002) 2191-2201
35. Oiwa Y., Yoshimura R., Nakai K., and Itakura T. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease. Brain Res 947 2 (2002) 271-283
36. Grondin R., Zhang Z., Ai Y., Ding F., Walton A.A., Surgener S.P., et al. Intraputamenal infusion of exogenous neurturin protein restores motor and dopaminergic function in the globus pallidus of MPTP-lesioned rhesus monkeys. Cell Transplant 17 4 (2008) 373-381
37. Rosenblad C., Kirik D., Devaux B., Moffat B., Phillips H.S., and Bjorklund A. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle. Eur J Neurosci 11 5 (1999) 1554-1566
38. Choi-Lundberg D.L., Lin Q., Chang Y.N., Chiang Y.L., Hay C.M., Mohajeri H., et al. Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 275 5301 (1997) 838-841
39. Bilang-Bleuel A., Revah F., Colin P., Locquet I., Robert J.J., Mallet J., et al. Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease. Proc Natl Acad Sci USA 94 16 (1997) 8818-8823
40. Kirik D., Rosenblad C., Bjorklund A., and Mandel R.J. Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J Neurosci 20 12 (2000) 4686-4700
41. Gasmi M., Herzog C.D., Brandon E.P., Cunningham J.J., Ramirez G.A., Ketchum E.T., et al. Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease. Mol Ther 15 1 (2007) 62-68
42. Gasmi M., Brandon E.P., Herzog C.D., Wilson A., Bishop K.M., Hofer E.K., et al. AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease. Neurobiol Dis 27 1 (2007) 67-76
43. Eslamboli A., Cummings R.M., Ridley R.M., Baker H.F., Muzyczka N., Burger C., et al. Recombinant adeno-associated viral vector (rAAV) delivery of GDNF provides protection against 6-OHDA lesion in the common marmoset monkey (Callithrix jacchus). Exp Neurol 184 1 (2003) 536-548
44. Wang L., Muramatsu S., Lu Y., Ikeguchi K., Fujimoto K., Okada T., et al. Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease. Gene Ther 9 6 (2002) 381-389
45. Kordower J.H., Herzog C.D., Dass B., Bakay R.A., Stansell III J., Gasmi M., et al. Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Ann Neurol 60 6 (2006) 706-715
46. Nutt J.G., Burchiel K.J., Comella C.L., Jankovic J., Lang A.E., Laws Jr. E.R., et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 60 1 (2003) 69-73
47. Slevin J.T., Gash D.M., Smith C.D., Gerhardt G.A., Kryscio R., Chebrolu H., et al. Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal. J Neurosurg 106 4 (2007) 614-620
48. Kordower J.H., Palfi S., Chen E.Y., Ma S.Y., Sendera T., Cochran E.J., et al. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol 46 3 (1999) 419-424
49. Gill S.S., Patel N.K., Hotton G.R., O'Sullivan K., McCarter R., Bunnage M., et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 9 5 (2003) 589-595
50. Patel N.K., Bunnage M., Plaha P., Svendsen C.N., Heywood P., and Gill S.S. Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study. Ann Neurol 57 2 (2005) 298-302
51. Marks Jr. W.J., Ostrem J.L., Verhagen L., Starr P.A., Larson P.S., Bakay R.A., et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol 7 5 (2008) 400-408